Acta Med. 2010, 53: 225-228

https://doi.org/10.14712/18059694.2016.81

Plasma Interleukin-6 Level is Associated with NT-proBNP Level and Predicts Short- and Long Term Mortality in Patients with Acute Heart Failure

Radek Pudila, Miloš Tichýb,c, Ctirad Andrýsd, Vít Řeháčekb, Václav Bláhae, Jan Vojáčeka, Vladimír Paličkac

aCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, 1st Department of Medicine, Czech Republic
bCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Transfusion Medicine, Czech Republic
cCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Biochemistry and Diagnostics, Czech Republic
dCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Czech Republic
eUniversity of Defence Brno, Faculty of Military Health Sciences Hradec Králové, Czech Republic

Received February 20, 2010
Accepted June 25, 2010

Objectives: Interleukin 6 plays an important role in chronic heart failure (HF), but little is known about its involvement in acute decompensated heart failure (ADHF). The aim of our study is to evaluate the prognostic role of interleukin 6 (IL-6) in the patients with ADHF. Methods: Plasma levels of interleukin IL-6, N-terminal pro brain natriuretic peptide levels, and clinical covariates were measured in 92 patients with ADHF. Survival was followed up to 12 months, and prognostic factors were evaluated. Results: Elevated plasma IL-6 levels were increased in nonsurvivors and were associated with 1-year mortality (p<0.01). Plasma IL-6 levels were associated with plasma NT-proBNP levels. In multivariate analysis, increased plasma IL-6 and NT-proBNP levels remained strong independent predictors of 1-year mortality. Conclusions: Plasma IL-6 levels provide important prognostic information in the patients with ADHF. Measurement combining plasma IL-6 and NT-proBNP should serve as a powerful prognostic tool of multimarker strategy in patients with acute decompensated heart failure.

Funding

The study was supported by the research projects of the Charles University Prague No. MSM0021620817 and MZO 00179906.

References

15 live references